HUMAN MONOCLONAL ANTIBODIES

我们的目标是定义自身免疫反应的性质 慢性特发性血小板减少性紫癜(ITP)患者。在.期间 在过去的一年里，我们分离出了一系列杂交细胞系，这些杂交细胞系产生了 抗血小板抗原的人类自身抗体。这些混血儿是 将EBV转化的ITP患者淋巴细胞与 抗6TG的NS-1小鼠骨髓瘤-人B淋巴细胞异源杂交细胞 线路，按F6。两株杂交瘤细胞分泌的单抗 已被确定与血小板蛋白或糖蛋白发生反应 分子量约10万道尔顿，以及抗体 由另一条线路分泌，与一系列 血小板相关蛋白或糖蛋白。 具体地说，我们现在希望1)准备一个体细胞杂交库 分泌人类抗血小板自身抗体；并检查2) 血清学和生化特异性，以及3)同型和 抗血小板单抗自身抗体的独特型特征。 然后我们将使用这些试剂来确定它们之间的关系 血清抗血小板的同型、独特型和分子特异性 抗体和疾病转归。我们的长期目标是利用这一点 为治疗慢性阻塞性肺疾病开发免疫学方法的信息 ITP。

Our objective is to define the nature of the autoimmune response in patients with chronic idiopathic thrombocytopenic purpura (ITP). During the past year we have isolated a series of hybrid cell lines that produce human autoantibodies against platelet antigens. These hybrids were prepared by fusing EBV transformed lymphocytes from patients with ITP with a 6TG resistant NS-1 mouse myeloma-human B lymphocyte heterohybrid cell line, F6. Monoclonal antibody secreted by two of the hybrid cell lines have been identified to react with a platelet protein or glycoprotein with a molecular weight of approximately 100,000 daltons, and an antibody secreted by another line reacts with a determinant shared by a series of platelet associated proteins or glycoproteins. Specifically, we now wish to 1) prepare a library of somatic cell hybrids which secrete human antiplatelet autoantibody; and examine 2) the serological and biochemical specificity, as well as 3) the isotypic and idiotypic characteristics of the monoclonal antiplatelet autoantibodies. We will then use these reagents to 4) determine the relationship between the isotype, idiotype, and molecular specificity of serum antiplatelet antibodies and disease outcome. Our long-range goal is to use this information to develop immunologic methods for the treatments of chronic ITP.